New Delhi, Feb 20 (PTI) Suven Life Sciences has secured a product patent each from India and South Korea for treatment of disorders associated with neuro-degenerative diseases. Also Read - Rohit Chadda, The Turnaround CEO Carved Out Another Success Story in 2020

The patents are valid through 2029 and 2033 respectively, the company said in a BSE filing. Also Read - Monsoon Session Day 2: Lok Sabha Passes Essential Commodities Bill to Raise Farmer Income, Boost Agri Sector | Highlights

“We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena, that are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said. Also Read - 'Jammu And Kashmir to Reopen For Tourism Soon', Says J&K Administration

Suven Life said the granted claims of the patents are being developed as therapeutic agents and useful in treatment of cognitive impairment associated with neuro-degenerative disorders like Alzheimer’s disease, Parkinson and Schizophrenia.

Suven shares were trading 2.28 per cent higher at Rs 195.55 on BSE in morning session.

This is published unedited from the PTI feed.